According to a press release from the German-American biotechnology company Immunic Therapeutics, the Company recently began a proof-of-concept trial for its investigational primary sclerosing cholangitis treatment, IMU-838. About Primary Sclerosing…
In the post-Sputnik era, science was king—or so says Peter Agre as he recalls the golden age of science. But, when is it wise to dismiss the “ivory tower” mentality…
With a title about courage, you might think that I am going to write about facing fierce enemies, not running from brutal battles, and boldly standing on blood-stained ground in…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
